Sprifermin for Knee Osteoarthritis

How is sprifermin intended to help knee osteoarthritis?

Sprifermin is a manufactured form of fibroblast growth factor 18, a protein involved in cartilage biology. Researchers administered it directly into the knee to investigate whether stimulating cartilage-producing cells could alter joint structure. This approach addresses a different treatment goal from simply reducing pain. Its clinical development illustrates the broader challenge facing cartilage-restoring therapies: showing that a biological effect produces a meaningful benefit for patients.

The phase 2 FORWARD trial randomly assigned 549 adults with symptomatic knee osteoarthritis to sprifermin regimens or placebo. Its main assessment measured cartilage thickness using MRI after two years. Higher-dose treatment increased thickness relative to placebo, while overall symptom scores did not improve significantly more than with placebo. Published in 2019, these are established findings being revisited for their relevance to regenerative treatment research. [FORWARD randomized trial](https://pmc.ncbi.nlm.nih.gov/articles/PMC6784851/)

Did cartilage growth lead to lasting pain relief?

The five-year report, published in 2021, found that the cartilage-thickness advantage persisted in the group receiving the highest dose most frequently. However, pain improved substantially across all groups, including placebo. Only 378 participants completed five-year follow-up, which also matters when interpreting longer-term outcomes. A lasting imaging difference therefore cannot, by itself, establish that people walk more comfortably or need fewer additional treatments. [Five-year FORWARD results](https://pubmed.ncbi.nlm.nih.gov/33962962/)

An exploratory analysis suggested a possible pain benefit among participants with narrower joint spaces and greater initial pain. That subgroup was examined after the fact, and the uncertainty around its five-year pain estimate included no treatment difference. It provides a hypothesis for another trial, rather than confirmation of who benefits. Most reported adverse events were mild or moderate and considered unrelated to treatment, but these findings cannot exclude uncommon harms. [Long-term efficacy and safety analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC8292562/)

What does this evidence mean for osteoarthritis treatment?

The practical lesson is to distinguish a promising scan result from a treatment that reliably improves life. Future trials can test whether structural changes accompany sustained improvements in pain and function. They also need sufficient follow-up to assess safety and outcomes such as joint replacement. For sprifermin, the unresolved relationship between cartilage growth and symptoms is central to interpreting the published evidence; the existing studies should not be presented as proof that osteoarthritis has been reversed.

Meanwhile, NICE guidance recommends therapeutic exercise tailored to the individual and weight management when appropriate. It recommends topical nonsteroidal anti-inflammatory drugs for knee osteoarthritis, with oral options considered according to individual risks if topical treatment is unsuitable or ineffective. Corticosteroid injections may provide short-term relief when other medicines are unsuitable or unsuccessful, or help someone participate in exercise. These recommendations offer a practical treatment framework while cartilage-restoring approaches undergo evaluation. [NICE osteoarthritis guidance](https://www.nice.org.uk/guidance/NG226/chapter/recommendations)